Two clinician-researchers are suggesting that more emphasis should be placed on maximizing the cost-benefit assessment of a precision medicine approach to testing and treating metastatic non–small-cell lung cancer (NSCLC), particularly with patient survival and the duration of treatment increasing appreciably.
San Francisco, CA—Transformative changes in cancer therapy will require new models for clinical research and practice. Retrofitting current knowledge into traditional paradigms is suboptimal and will slow the progress in discovering effective targeted agents, said Razelle Kurzrock, MD, Director, Center for Personalized Cancer Therapy and Clinical Trials Office, Moores Cancer Center, University of California, San Diego, at the Third Annual PMO Live Conference, a Global Biomarkers Consortium Initiative.
Los Angeles, CA—Radical changes are resulting from the recent shift from volume-based to value-based reimbursement and care. The fundamental shift in reimbursement models is proving disruptive, as providers and payers are exploring integration opportunities with their continuum partners that may redefine the current reimbursement paradigm, said Jonathan Bluth, MBA, Vice President, Healthcare Investment Banking, Deloitte Corporate Finance LLC, Los Angeles, CA, at the Fourth Annual Conference of the Association for Value-Based Cancer Care.
Cancer care requires the use of many experts and services, in addition to the care provided by medical oncologists. Access to patient support services is an integral component of cancer care. Value-Based Cancer Care (VBCC) asked Mark J. Krasna, MD, Corporate Medical Director of Oncology, Meridian Health, Jersey Shore University Medical Center, Neptune, NJ, to describe key characteristics of a multidisciplinary approach to cancer care and its unique value for patients, providers, and the entire care continuum.
Miami, FL—The best bet for preventing the reactivation of latent hepatitis B virus (HBV) infection before adjuvant chemotherapy is to screen patients with early-stage breast cancer for the virus, according to data presented at the 2014 Society for Medical Decision Making annual North American meeting. Lead investigator William W. L. Wong, MMath, PhD, Assistant Professor and Decision Modeller, Toronto Health Economics and Technology Assessment Collaborative, University of Toronto, Ontario, Canada, and his colleagues showed that it is cheaper in the long run to screen everyone than to test only individuals who are most likely to harbor HBV infection.
New York, NY—The oncology community is abuzz with the promise of immunotherapy, sparked by the success of immunotherapeutic approaches in advanced melanoma. There is major interest in studying immunotherapy in other cancers, including breast and lung cancer.
New York, NY—Investigators at Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, Rockefeller University, and the National Cancer Institute are moving forward in their understanding of the adverse association between obesity and breast cancer. Preliminary studies show associations between adipocytes, aromatase, proinflammatory cytokines, low-grade chronic inflammation, and breast tumors. Improved understanding of these associations will potentially lead to targeted interventions, said Clifford A. Hudis, MD, Chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, and immediate Past President of the American Society of Clinical Oncology, at the 2014 Chemotherapy Foundation Symposium.
New York, NY—The high cost of cancer drugs makes the potential for biosimilar oncology drugs of particular interest to oncologists and to patients. To date, no oncology biosimilar has been approved by the FDA. Global studies of trastuzumab (Herceptin) biosimilars are currently under way. One trastuzumab biosimilar is already approved in South Korea, and the company is in the process of filing for its regulatory approval in Europe. During the next 3 years, this biosimilar will likely be approved in the United States.
  • Jakafi Gets New Indication for Use in Patients with Polycythemia Vera
  • Cyramza Approved in Combination with Docetaxel for Metastatic NSCLC
  • Cyramza plus Paclitaxel for Advanced Gastric Cancer After Chemotherapy
  • Blincyto First Immunotherapy Approved for B-Cell Acute Lymphoblastic Leukemia
  • Avastin plus Chemotherapy for Platinum-Resistant Gynecologic Cancers
  • Immunotherapy Vaccine for Patients with Newly Diagnosed Glioblastoma Shows Promising Results
  • High Immunologic Response Seen with Oral Vaccine for Pancreatic Cancer in a Phase 1 Extension Trial
  • M.D. Anderson Cancer Center Launches New Programs After FDA’s Approval of Novel HPV Vaccine
Page 3 of 4
Results 21 - 30 of 33
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology